Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

Who Took Part

The study group was 20 women.

PubMed indexes the participants as adults, women only.

How the Study Was Run

The design is described as randomized, single-blind and placebo-controlled.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the women, was kept unaware of whether Semaglutide was given.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

GE was assessed after ingestion of [99mT c] colloid in a pancake labelled with radiopharmaceutical by scintigraphy using sequential static imaging and dynamic acquisition at baseline and at Week 13.

Estimation of GE was obtained by repeated imaging of remaining [99mT c] activity at fixed time intervals over the course of 4 hours after ingestion.

What Was Measured

The subject headings attached to it are Gastric Emptying, Polycystic Ovary Syndrome, Obesity and Semaglutide.

Author keywords: PCOS and scintigraphy.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Semaglutide in 20 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, all human trials.